Literature DB >> 12895259

Alternative medicines and the liver.

Edward Fogden1, James Neuberger.   

Abstract

Complementary and Alternative Medicine (CAM) is a heterogeneous group of theories and practices that are becoming increasingly popular in the West - between 20% and 65% of patients use CAM on a regular basis. In the UK, CAM is provided by over a third of general practitioners as well as by hospitals. The subject of much debate in both the lay and medical press, CAM is subject to increasing scrutiny from clinical research. In this review, we discuss the available evidence for herbal medicines, including that for silymarin, glycyrrhizin, Chinese herbal medicines and other herbal mixtures. We also review evidence regarding the safety of herbal medicines, both in terms of hepatotoxicity and drug interactions. We conclude that although CAM may be of benefit in the treatment of liver disease, the available evidence is insufficient to recommend any of the available therapies. CAM has not yet been well studied in liver disease and rigorous evaluation with well-designed double-blind randomised controlled trails is required. Doctors need to be aware of the widespread use of CAM, ask their patients specifically regarding their use of CAM and be aware of the potential for hepatotoxicity and interactions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895259     DOI: 10.1034/j.1600-0676.2003.00843.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  9 in total

1.  Counteracting effect of glycyrrhizin on the hemostatic abnormalities induced by Bothrops jararaca snake venom.

Authors:  Mariane Assafim; Marcos S Ferreira; Flávia S Frattani; Jorge A Guimarães; Robson Q Monteiro; Russolina B Zingali
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 2.  Liver enzyme alteration: a guide for clinicians.

Authors:  Edoardo G Giannini; Roberto Testa; Vincenzo Savarino
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

3.  Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.

Authors:  Ayako Suzuki; Raul J Andrade; Einar Bjornsson; M Isabel Lucena; William M Lee; Nancy A Yuen; Christine M Hunt; James W Freston
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

Review 4.  Complementary and alternative medicine in the treatment of chronic liver disease.

Authors:  Robert G Batey; Ses J Salmond; Alan Bensoussan
Journal:  Curr Gastroenterol Rep       Date:  2005-02

5.  Complementary and alternative medicine use in chronic liver disease patients.

Authors:  Leah M Ferrucci; Beth P Bell; Kathy B Dhotre; M Michele Manos; Norah A Terrault; Atif Zaman; Rosemary C Murphy; Grace R Vanness; Ann R Thomas; Stephanie R Bialek; Mayur M Desai; Andre N Sofair
Journal:  J Clin Gastroenterol       Date:  2010-02       Impact factor: 3.062

6.  Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study.

Authors:  Nilesh Chande; Maggie Laidlaw; Paul Adams; Paul Marotta
Journal:  Dig Dis Sci       Date:  2006-07       Impact factor: 3.487

Review 7.  Therapeutic potential of chinese herbal medicines in alcoholic liver disease.

Authors:  Kuan-Hung Lu; Chun-Ting Liu; Rajasekaran Raghu; Lee-Yan Sheen
Journal:  J Tradit Complement Med       Date:  2012-04

Review 8.  Elevated Liver Enzymes in Asymptomatic Patients - What Should I Do?

Authors:  Mazyar Malakouti; Archish Kataria; Sayed K Ali; Steven Schenker
Journal:  J Clin Transl Hepatol       Date:  2017-09-21

9.  Mechanism of protection of rat hepatocytes from acetaminophen-induced cellular damage by ethanol extract of Aerva lanata.

Authors:  Chithambaram Sujatha Anusha; Hariharan Sini; Bhaskara Prakashkumar; Kottayath Govindan Nevin
Journal:  Interdiscip Toxicol       Date:  2020-04-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.